Wednesday, February 10, 2010, 4:27am EST - Canadian Markets open in 5 hours and 3 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

IR Biosciences Holdings Inc. (IRBS.OB)

 On Feb 9: 0.35 USD   0.00 (0.00%)  
MORE ON IRBS.OB
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
IR BIOSCIENCES HLDGS (OTC BB:IRBS.OB) Delayed quote dataEdit
Last Trade: 0.35 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.35
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 2.00
Day's Range: N/A - N/A
52wk Range: 0.02 - 1.18
Volume: 0
Avg Vol (3m): 17,996.8
Market Cap: 4.65M
P/E (ttm): N/A
EPS (ttm): -0.69
Div & Yield: N/A (N/A%)
IR Biosciences Holdings Inc. (IRBS.OB)
1d  5d  3m  6m  1y  2y  5y  max 
 Add IRBS.OB to Portfolio   Download Data

HEADLINES
• National Cancer Institute Initiates Studies on ImmuneRegen BioSciences' Vaccine Adjuvant Candidate
Marketwire (Wed, Jan 27)
• IR Biosciences' ImmuneRegen (OTCBB: IRBS) Getting Attention for Its Adult Stem Cell Active Compound
Marketwire (Tue, Jan 26)
• ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study of Homspera(R) in Treating Highly Pathogenic Influenza
Marketwire (Tue, Jan 5)
• ImmuneRegen BioSciences(R) Summarizes Previous 9 Months of Advances as Homspera(R) Development Continues
Marketwire (Thu, Dec 24)
• ImmuneRegen BioSciences'(R) Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine
Marketwire (Mon, Dec 21)
• ImmuneRegen BioSciences'(R) Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant
Marketwire (Mon, Dec 14)
• IR BIOSCIENCES HOLDINGS INC Financials
EDGAR Online Financials (Sat, Nov 21)
• IR BIOSCIENCES HOLDINGS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 16)
• ImmuneRegen BioSciences(R) Reports Positive Results of Homspera(R) in Treating Highly Pathogenic Influenza
Marketwire (Tue, Nov 10)
• ImmuneRegen BioSciences(R) to Further Homspera(R) Research in Study Funded by U.S. Government
Marketwire (Thu, Oct 22)
More Headlines for IRBS.OB...
ANALYST
EPS Est (next year) (Dec-69) : N/A
EPS Est (in 2 years) (Dec-69) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
IR BioSciences Holdings, Inc., a development-stage biotechnology company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of Homspera and its derivatives, Radilex and Viprovex.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices